The research, published in the Journal of Neurology by a team at Karolinska Institutet, drew on the Environmental Investigation in Multiple Sclerosis, or EIMS, a population-based case-control study that has been running in Sweden since 2005. The investigators analyzed data from 3,008 people newly diagnosed with multiple sclerosis and 5,773 matched controls drawn from the national population register. Crucially, the team restricted their analysis to participants whose disease onset, or corresponding reference year among controls, occurred within five years before study enrollment, a design choice intended to ensure that reported exercise habits genuinely preceded the disease rather than being shaped by its early, invisible stages.

Participants reported their leisure-time physical activity five years before inclusion, categorized into four levels ranging from largely sedentary living to sweat-inducing exercise at least three times per week. The lowest level corresponded to less than two hours per week of light activity such as walking or cycling, while the highest required at least thirty minutes of vigorous exercise three or more times weekly. Sun exposure over the same period was captured through a composite index combining sunbathing in Sweden, travel to sunnier countries, and use of sunbeds, with scores summed into a scale ranging from three to twelve.

At first glance, the results seemed to confirm what many earlier studies had suggested. In a model adjusting only for age, sex, and residential area, the most active participants had a 22 percent lower risk of multiple sclerosis than the least active, with an odds ratio of 0.78. A clear downward trend emerged across the activity levels, with each step up the activity ladder associated with roughly 8 percent lower odds of disease. For anyone who has followed the exercise-prevention literature, this is exactly the pattern one would expect to see.

But the picture changed dramatically once the researchers accounted for the full web of lifestyle and environmental factors that travel alongside physical activity. After adjusting for ancestry, educational level, smoking status, alcohol consumption, body mass index at age twenty, and sun exposure, the odds ratio for high versus low activity drifted to 0.94, a figure statistically indistinguishable from no effect at all. The per-level trend estimate similarly weakened from 0.92 to 0.97. In other words, much of what looked like protection from exercise appeared to be protection from something else that active people tend to have more of, most notably sunshine.

The stratified analyses revealed the study’s most intriguing finding. Among participants with low sun exposure, defined as a composite index score below six, high physical activity remained associated with a 24 percent reduction in multiple sclerosis risk, with an adjusted odds ratio of 0.76 and a statistically significant inverse trend across activity levels. Among those with high sun exposure, no such association existed; the odds ratio was a flat 0.97. Formal statistical testing confirmed that the interaction between physical activity and sun exposure was unlikely to be a fluke, with a p-value of 0.01, and model-predicted probabilities visualized the gradient clearly: the protective slope of exercise was steepest in the sun-deprived and vanished as sun exposure rose.

Skeptics might argue that physical activity is simply a proxy for time spent outdoors, and that sunshine, not exercise, does the real work. To test this, the team conducted a sensitivity analysis in a subgroup of participants recruited after 2015 who had provided detailed information on time spent outdoors during summer leisure and at work. Remarkably, the inverse association between physical activity and multiple sclerosis risk persisted essentially unchanged after additional adjustment for outdoor time, with the odds ratio per activity level moving only from 0.87 to 0.88. This suggests that exercise itself, or something closely tied to it beyond mere outdoor exposure, may genuinely matter for people whose sun exposure is otherwise low.

What biological mechanisms could underlie such a pattern? Regular exercise is known to exert systemic anti-inflammatory effects, influencing cytokine profiles, metabolic regulation, adiposity-related inflammation, and the signaling of myokines, molecules released by contracting muscle. These pathways intersect with the immune processes implicated in the autoimmune attack on the central nervous system that defines multiple sclerosis. Sun exposure, meanwhile, is the principal driver of vitamin D production and has well-documented immunomodulatory effects, and low sun exposure has previously been shown in the same Swedish cohort to raise multiple sclerosis risk both directly and indirectly. One plausible interpretation is that sunlight and exercise act on overlapping biological pathways, so that the marginal benefit of exercise becomes visible only when the sun-related pathway is underactive.

The authors are careful to emphasize the caveats. All exposures were self-reported retrospectively, opening the door to recall bias, and the interval between the reported activity period and clinical onset varied among participants. Reverse causation remains a serious concern, because multiple sclerosis is increasingly recognized to have a prodromal phase, sometimes years before diagnosis, in which fatigue, reduced exercise tolerance, pain, and subtle neurological changes may quietly reshape a person’s activity habits. The broad four-level activity categories also cannot capture every nuance of duration, intensity, and seasonal variation, and the sun exposure index is an imperfect stand-in for total ultraviolet radiation dose. The sun-exposure interaction, the team notes, should be considered exploratory until replicated.

Still, the study’s strengths are considerable: a population-based design, nearly 3,000 incident cases, high participation rates, and unusually comprehensive confounder data, including a check against residual confounding by population structure using genetic principal components. The takeaway for the public is not that exercise is useless against multiple sclerosis, but that its potential preventive role is context-dependent, most apparent in people with limited sun exposure and robust even after accounting for time outdoors. As the authors conclude, physical activity should be understood in relation to sun exposure, outdoor behavior, and the broader lifestyle patterns in which it is embedded, a reminder that in disease-prevention research, no single behavior operates in isolation.

Subject of Research: The association between leisure-time physical activity, sun exposure, and risk of developing multiple sclerosis

Article Title: Leisure-time physical activity, sun exposure, and multiple sclerosis risk: a population-based case–control study

Article References: Guo, Q., Olsson, T., Alfredsson, L., & Hedström, A. K. (2026). Leisure-time physical activity, sun exposure, and multiple sclerosis risk: a population-based case–control study. Journal of Neurology, 273(10), Article 623. https://doi.org/10.1007/s00415-026-14170-9

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14170-9

Keywords: multiple sclerosis, physical activity, sun exposure, case-control study, epidemiology, autoimmune disease, vitamin D, outdoor activity, risk factors, Karolinska Institutet, disease prevention, Journal of Neurology

Efgartigimod works through an elegant molecular trick. It is a human immunoglobulin G1 (IgG) antibody Fc fragment, engineered to bind with unusually high affinity to the neonatal Fc receptor (FcRn), the cellular recycling machinery that normally protects IgG antibodies from degradation and gives them their characteristically long half-life in the bloodstream. By occupying FcRn, efgartigimod interrupts this recycling loop, so circulating IgG, including the pathogenic autoantibodies that drive diseases like gMG and CIDP, is cleared faster. Importantly, the drug does not suppress antibody production or blunt immune responses to vaccination, and it does not lower albumin levels or raise cholesterol, distinguishing it from broadly immunosuppressive therapies such as glucocorticoids, azathioprine, mycophenolate mofetil, or B cell-depleting agents.

The original subcutaneous formulation contained a fixed 1000-mg dose of efgartigimod at 180 mg/ml in a 5.6-ml volume, supplied in a single-dose vial that a health care provider had to draw up with a separate syringe. The new prefilled syringe packs the same 1000-mg dose into 5.0 ml at a higher concentration of 200 mg/ml, and it was approved in the United States in April 2025 for adults with acetylcholine receptor autoantibody-positive generalized myasthenia gravis and for adults with CIDP. The coformulation with recombinant human hyaluronidase PH20 is what makes such a large subcutaneous volume feasible: the enzyme locally depolymerizes hyaluronan in the subcutaneous space, temporarily dissolving the structural barrier to bulk fluid flow so the drug can disperse and be absorbed more readily.

The first question the researchers tackled was whether the prefilled syringe is pharmacologically interchangeable with the vial-and-syringe presentation. In a Phase 1, open-label, randomized, two-period crossover bioequivalence study (ClinicalTrials.gov identifier NCT05817435), 72 healthy participants each received a single health care provider-administered injection by both routes, serving as their own controls. Serum efgartigimod concentrations were measured with a validated ligand-binding electrochemiluminescence immunoassay with a lower limit of quantification of 200 ng/ml, and the primary endpoints were the maximum observed concentration (Cmax) and the area under the concentration-time curve from zero to infinity (AUC0-inf).

The bioequivalence criterion was met decisively. The 90 percent confidence intervals for the geometric least-squares mean ratios of both Cmax and AUC0-inf fell entirely within the predefined acceptance range of 80.0 to 125.0 percent, the regulatory standard for demonstrating that two formulations deliver equivalent systemic exposure. After injection, efgartigimod concentrations rose to a plateau, with a median time to peak concentration of 48.0 hours for the prefilled syringe versus 72.0 hours for the vial and syringe, and individual values ranging from 12.0 to 119.3 hours. Once the plateau was reached, serum concentrations declined gradually with similar half-lives for both presentations, and other pharmacokinetic parameters were likewise comparable between the two arms.

Safety in the bioequivalence study was reassuring. The drug was well tolerated by both routes, with no fatal or serious adverse events and no discontinuations attributed to adverse events. A single grade 3 or higher event, a blood pressure increase in one participant who received the vial-and-syringe formulation, was judged unrelated to treatment. Injection site reactions occurred in 50.7 percent of participants using the prefilled syringe and 59.7 percent using the vial and syringe, all of grade 1 or 2 severity, and all resolved by the end of the study except one that was resolving. A post hoc analysis showed mean injection durations of roughly 31 seconds in both groups, and no anaphylactic or hypersensitivity reactions were observed.

A second Phase 1 study asked a deceptively simple question: how fast can a large, viscous subcutaneous volume be pushed without causing problems? All 48 randomized healthy participants completed this randomized, open-label crossover trial, in which efgartigimod PH20 SC was delivered over 20, 30, 45, or 60 seconds using an infusion pump with a disposable syringe and a 27-gauge ultra-thin-wall needle. Every participant across every speed group received at least 90 percent of the full injection volume in both dosing periods, and mean fluid leakage or backflow at the injection site was negligible and essentially identical across groups, at 0.0122 ml in the first period and 0.0085 ml in the second. More than 87 percent of participants said one hour after injection that they would be willing to receive the administration again, local pain scores dropped significantly within five minutes across all speed groups, and all adverse events were mild to moderate, with no serious events or discontinuations.

The third component comprised two human factors validation studies, designed according to US Food and Drug Administration guidance for combination products, that tested whether real users could handle the device safely. Fifteen participants with gMG, fifteen with CIDP, and fifteen lay caregivers of family members with these diseases were given the prefilled syringe and its instructions for use, but no training whatsoever. In a simulated home environment, each participant stored the device overnight and then performed an unaided simulated injection into an injection pad, placed over their own clothes for patients or on a manikin for caregivers. The results were striking: all 45 participants successfully refrigerated, prepared, injected, and disposed of the prefilled syringe, delivering the full dose in an average of 30 seconds, with no performance differences between patients and caregivers and no use errors that could cause harm. All 45 also correctly located and identified 28 pieces of critical safety information in the instructions, and every participant said they believed they could give weekly injections with the product if needed.

The authors acknowledge one methodological caveat: the injection speed study used an infusion pump rather than the prefilled syringe device itself, which prevents firm conclusions about the optimal speed of the PFS specifically. However, the formulation tested had the same volume and viscosity as that used in the bioequivalence and human factors studies, which did employ the device, so the data collectively support the feasibility and safety of a rapid, roughly 30-second injection of efgartigimod PH20 SC in general. The researchers also note that the studies were funded by argenx, the drug’s developer, and that several of the authors are company employees, factors readers should weigh when interpreting the uniformly positive findings.

Even with those caveats, the implications for patients are substantial. For chronic conditions like gMG and CIDP, where treatment continues indefinitely, aligning therapy with patient preferences for route of administration has been linked to greater satisfaction, better quality of life, and improved adherence. A prefilled syringe eliminates the steps of vial handling and dose drawing, improves dosing accuracy, and particularly benefits patients with impaired manual dexterity, coordination, or vision, while reducing health care resource utilization and waste. Taken together, the bioequivalence, injection speed, and human factors data indicate that a rapid, high-volume subcutaneous injection of efgartigimod PH20 from a prefilled syringe is safe, feasible, and usable, offering patients and their caregivers a quick, flexible option for receiving treatment either in a clinic or at home, and potentially easing the daily burden of living with IgG-mediated autoimmune disease.

Subject of Research: Pharmacokinetics, injection speed, and usability of a prefilled syringe for subcutaneous efgartigimod PH20 in IgG-mediated autoimmune diseases

Article Title: Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administered with a Prefilled Syringe

Article References: De Muynck, C., Noukens, J., Allosery, K., Cettour-Rose, C., Pastouret, S., Andre, A. D., & Borgions, F. (2026). Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administered with a Prefilled Syringe. Advances in Therapy. https://doi.org/10.1007/s12325-026-03733-x

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03733-x

Keywords: efgartigimod, prefilled syringe, bioequivalence, myasthenia gravis, CIDP, neonatal Fc receptor, hyaluronidase PH20, subcutaneous injection, pharmacokinetics, human factors study, autoimmune disease, self-administration

The study, led by Tomás José González-López of Hospital Universitario de Burgos and colleagues across 22 Spanish centers, analyzed 72 adults with ITP drawn from a broader national cohort of 174 patients who had received the drug. The median age of participants was 67 years, and 55.6 percent were women, a demographic profile that reflects the typical real-world ITP population far better than the carefully selected patients enrolled in pharmaceutical registration trials. Half of the patients carried at least one comorbidity on the Charlson Comorbidity Index, and roughly a quarter had experienced bleeding in the month before starting fostamatinib, underscoring the clinical urgency that often drives treatment decisions in this disease.

ITP is an acquired immune-mediated disorder in which platelet counts fall because of a double hit: antibodies and cytotoxic T lymphocytes accelerate platelet destruction in the spleen and elsewhere, while defective megakaryocyte maturation impairs the production of replacement platelets in the bone marrow. The clinical course is highly variable. Some patients remain asymptomatic despite platelet counts well below 100 × 10⁹ per liter, while others suffer significant mucocutaneous bleeding or develop chronic, relapsing disease that demands years of therapy. Beyond the bleeding risk itself, ITP carries a substantial burden on quality of life and healthcare resources, particularly for patients who cycle through multiple treatment lines without achieving durable control.

Standard first-line therapy remains corticosteroids, sometimes supplemented by intravenous immunoglobulin when rapid platelet increases are needed. Although initial steroid responses are high, relapse after dose tapering is common, and many patients become corticosteroid-dependent with all the metabolic and infectious complications that entails. Second-line options include thrombopoietin receptor agonists such as eltrombopag and romiplostim, the anti-CD20 antibody rituximab, and splenectomy. Each has drawbacks: TPO receptor agonists require continuous administration and raise concerns about thromboembolic risk in some patients, while rituximab and splenectomy can produce durable remissions but carry delayed onset, variable long-term efficacy, and procedure- or immunosuppression-related hazards. Guidelines therefore emphasize individualized sequencing, and the search for well-tolerated earlier options has intensified.

Fostamatinib attacks the disease from a different angle. As an oral inhibitor of spleen tyrosine kinase, or SYK, it interferes with Fcγ receptor signaling in macrophages, the scavenger cells that phagocytose antibody-coated platelets. By blocking this pathway, the drug reduces antibody-dependent platelet destruction rather than simply stimulating platelet production. Its efficacy and safety were established in the pivotal phase 3 FIT trials in patients with persistent and chronic ITP who had already received multiple prior therapies, leading to regulatory approval for chronic ITP in adults refractory to other treatments. But those trials, by design, tested the drug late in the disease course, leaving a gap in evidence about how it performs when introduced earlier.

The new Spanish study was designed to fill that gap. Patients received fostamatinib at the European Medicines Agency-approved starting dose of 100 milligrams twice daily, with escalation to 150 milligrams twice daily after four weeks if platelet responses were inadequate and tolerability permitted. Fifty-six point nine percent of patients ultimately required the higher dose, typically after a median of 24 days. Forty patients, or 55.5 percent, took fostamatinib as monotherapy throughout their treatment, while the remainder used it alongside tapering corticosteroids, immunoglobulin, or other agents. The median time from ITP diagnosis to fostamatinib initiation was 17 months, and the baseline platelet count stood at just 28 × 10⁹ per liter.

The effectiveness results were striking. Overall, 83.3 percent of patients achieved a response, defined as a platelet count of at least 30 × 10⁹ per liter with at least a twofold increase from baseline, resolution of bleeding, and no rescue therapy within the preceding eight weeks. Complete response, meaning a platelet count of at least 100 × 10⁹ per liter, was reached by 65.3 percent. When fostamatinib was used as second-line therapy, 76.0 percent responded, with 56.0 percent achieving complete response; in the third-line setting, the figures rose to 87.2 percent and 70.2 percent respectively. The median time to platelet response was a brisk 10.5 days, and patients reached their peak platelet counts, a median of 140 × 10⁹ per liter, after a median of 62 days. Across the 42-month observation window, patients spent a cumulative 76.8 percent of their time in response.

Exploratory subgroup analyses hinted at interesting patterns, though the investigators caution that these were hypothesis-generating and based on small numbers. Response rates were higher among women than men, 92.5 versus 71.9 percent, and higher in chronic than in non-chronic ITP by the same margin. Patients previously treated with eltrombopag responded more often than those without such exposure, 96.3 versus 75.6 percent, while prior romiplostim exposure was associated with a lower rate. Notably, second-line use was associated with faster platelet recovery, a median of 32 days to peak count compared with 77 days for third-line use, suggesting that earlier introduction may speed benefit even when overall efficacy is similar. Twenty-seven point eight percent of patients discontinued the drug for insufficient effectiveness, and only four patients, 5.5 percent, managed to stop fostamatinib successfully after responding, indicating that the drug is best regarded as long-term maintenance therapy rather than a finite course.

Safety data were reassuring. Adverse events occurred in 44.4 percent of patients and were predominantly mild to moderate, with diarrhea, hypertension, and headache the most common complaints, generally manageable with symptomatic treatment. Only 15.3 percent of patients stopped the drug because of toxicity, and severe grade 3 to 4 events were infrequent. Three thromboembolic events occurred, two deep vein thromboses and one pulmonary embolism, but all three patients had established thrombotic risk factors unrelated to the drug, including advanced age, obesity, and immobilization. Given growing recognition that ITP itself carries an elevated thrombotic risk, the low incidence observed here, 4.2 percent, may represent a meaningful advantage for patients with cardiovascular comorbidities, a group well represented in this elderly cohort.

The findings align with a growing body of international real-world evidence, including the Spanish FOSTASUR study, the Italian GIMEMA ITP 1122 experience, and a post hoc analysis of the FIT trials that reported response rates of 94 percent and 86 percent for second- and third-line use respectively. The authors acknowledge the limitations inherent to an observational design without a control group, but the consistency across independent cohorts strengthens the case. Their conclusion is direct: fostamatinib should be considered earlier in the ITP treatment algorithm rather than reserved as a last resort, with prospective studies now needed to define the optimal timing and sequencing of a drug that, for many patients, may offer rapid, durable platelet recovery with an acceptable safety profile.

Subject of Research: Real-world effectiveness and safety of early-line fostamatinib therapy in adult immune thrombocytopenia

Article Title: Early Use of Fostamatinib in Immune Thrombocytopenia

Article References: González-López, T. J., Bermejo-Vega, N., Cardesa-Cabrera, R., Acedo, N., Luis-Navarro, J., Lakhwani, S., Bernat, S., Haces-Tirado, G. E., Galán, P., Lozano, M. L., Martínez-Carballeira, D., Hernández-Martin, R., Jimenez-Bárcenas, R., Navas-Elorza, B., Marcellini, S., Torres-Tienza, A., Perona-Blázquez, A., Benet, C., Fernandez-Jimenez, D., … García-Donás Gabaldón, G. (2026). Early Use of Fostamatinib in Immune Thrombocytopenia. Advances in Therapy. https://doi.org/10.1007/s12325-026-03769-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03769-z

Keywords: immune thrombocytopenia, fostamatinib, SYK inhibitor, second-line therapy, third-line therapy, platelet response, real-world study, hematology, autoimmune disease, drug safety, thrombosis risk, Spain

The study, a propensity-matched cohort analysis built on the TriNetX database, represents a methodological step forward in a field where much of the evidence has come from small, single-center case series. TriNetX aggregates deidentified electronic health records from large networks of healthcare organizations, allowing researchers to assemble cohorts of patients that would be impossible to recruit through any single clinic. Because the database is deidentified and publicly available in aggregated form, the authors note that the work was exempt from institutional review board review, a common and accepted practice for studies of this kind.

The central methodological challenge in any study of comorbidity is confounding. Children with vitiligo who see dermatologists are, by definition, children who interact with the healthcare system more often, which means they are also more likely to have psychiatric diagnoses recorded simply because someone is looking. Older children differ from younger ones, patients with other autoimmune conditions differ from those without, and socioeconomic factors shape both access to care and documentation of mental health problems. Propensity matching is a statistical technique designed to cut through this tangle. Rather than comparing all children with vitiligo to all children without it, the method pairs each vitiligo patient with one or more control patients who share the same measured characteristics, such as age, sex, race and comorbid conditions. Once the cohorts are balanced in this way, differences in psychiatric outcomes between the two groups can be attributed with greater confidence to the disease itself rather than to the characteristics that led one child to develop it and another not to.

The focus on Black pediatric patients is deliberate and clinically important. Vitiligo is equally prevalent across skin types, but its visual impact is not. On deeply pigmented skin, the loss of melanin produces stark, high-contrast patches that are difficult to conceal and difficult for others to ignore. Research on the psychosocial effects of vitiligo, including a systematic literature review by K. Ezzedine and colleagues published in the American Journal of Clinical Dermatology in 2021, has consistently documented elevated rates of low self-esteem, social anxiety, stigmatization and diminished quality of life among patients, with darker-skinned patients frequently reporting the greatest distress. The global VALIANT study, reported in JAMA Dermatology in 2023 by K. Bibeau, K. Ezzedine, J. E. Harris and colleagues, quantified this burden across countries and found substantial mental health and psychosocial quality-of-life impairment among vitiligo patients worldwide.

Children occupy a particularly vulnerable position in this landscape. Adolescence is precisely the developmental window in which appearance, peer acceptance and identity formation converge, and a visible skin condition during these years can shape social experience in lasting ways. Prior work has also established that pediatric mental and behavioral health care is unevenly distributed, with documented disparities affecting minority children. A study by J. A. Hoffmann, M. Alegría, K. Alvarez and colleagues in Pediatrics in 2022 examined disparities in pediatric mental and behavioral health conditions and highlighted how diagnosis, treatment access and outcomes diverge along racial and socioeconomic lines. Against that backdrop, the question of whether Black children with vitiligo experience excess psychiatric morbidity is not merely academic; it speaks to whether a visible, stigmatizing skin disease compounds existing inequities in mental health care.

The new analysis builds directly on earlier work by some of the same research community. A 2024 retrospective, single-center, case-control study by E. Strouphauer, S. Suhail, C. Mulinda and colleagues, published in JAAD International, examined the prevalence of psychiatric comorbidities and treatment initiation in African American pediatric patients with vitiligo. That study, limited to a single institution, provided an early signal that psychiatric comorbidity in this population deserved closer scrutiny. By moving to a large, multi-institutional database and applying propensity matching, the current research letter aims to test whether the signal holds when the comparison groups are statistically balanced and the sample is broadened far beyond one center.

The technical machinery behind such an analysis is worth unpacking, because it explains both the strengths and the limits of the findings. In a propensity-matched cohort design, researchers first define an index event, here a diagnosis of vitiligo in a Black pediatric patient, and then identify covariates measured around the time of that diagnosis. These covariates are fed into a model, typically logistic regression, that estimates each patient’s propensity score, essentially the probability of having vitiligo given their measured characteristics. Patients with vitiligo are then matched to patients without vitiligo who have near-identical propensity scores. After matching, the investigators compare the incidence of psychiatric diagnoses, such as anxiety disorders, depressive disorders, attention deficit hyperactivity disorder and adjustment disorders, between the two balanced cohorts. The approach mimics some features of a randomized trial, in which chance alone would determine group assignment, though it can only balance the characteristics that are measured and recorded in the data.

That last caveat matters. Electronic health records capture what clinicians document, and documentation is itself shaped by access, insurance status, health literacy and the well-documented tendency for the psychiatric symptoms of minority children to be under-recognized or differently coded. If Black children with vitiligo are less likely to be screened for depression or anxiety than their white counterparts, then any observed rate of psychiatric comorbidity in the database may understate the true burden. Conversely, if children with a visible skin condition receive more medical attention overall, some of the recorded psychiatric diagnoses could reflect detection rather than true excess disease. Propensity matching on measured covariates cannot fully resolve either problem, which is why the authors frame their work as a research letter, a concise contribution intended to establish an association and motivate further study rather than to settle the question definitively.

The broader context of vitiligo research adds another dimension to the findings. The disease has a complex relationship with autoimmunity and, as Verma and colleagues explored in a 2025 retrospective case-control investigation in Clinical Dermatology, a historically debated association with melanoma that continues to be revisited. Vitiligo is increasingly understood as a systemic immune condition with cutaneous manifestations, and its comorbidity profile, psychiatric and otherwise, is part of what defines it as a genuine medical disorder rather than a cosmetic curiosity. Recognizing the psychiatric dimension has practical consequences: dermatologists who treat pediatric vitiligo are often the first clinicians positioned to notice signs of psychological distress, and screening tools integrated into dermatology visits could route affected children toward mental health services earlier.

What the study ultimately underscores is that the burden of vitiligo cannot be measured in body surface area alone. For Black children, whose depigmented patches are highly conspicuous and who already navigate a healthcare system with documented mental health disparities, the disease arrives at an intersection of dermatological and psychiatric vulnerability. By leveraging a large deidentified database and a rigorous matching strategy, the authors have produced evidence that psychiatric comorbidity in this population warrants systematic attention from clinicians, researchers and health systems alike. The research letter, published in volume 318 of the Archives of Dermatological Research, is a compact contribution, but its implications reach well beyond its length: if the skin is the most visible organ, then the psychological wounds of losing its pigment deserve to be counted, treated and taken as seriously as the patches themselves.

Subject of Research: Psychiatric comorbidities in Black pediatric vitiligo patients assessed through a propensity-matched cohort analysis

Article Title: Psychiatric comorbidities in black pediatric vitiligo patients: a propensity-matched cohort analysis

Article References: Verma, K. K., Nguyen, K. T., Goldstein, D. R., Elbuluk, N., Tarbox, M. B., & Desai, S. R. (2026). Psychiatric comorbidities in black pediatric vitiligo patients: a propensity-matched cohort analysis. Archives of Dermatological Research, 318(1), Article 494. https://doi.org/10.1007/s00403-026-04997-7

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04997-7

Keywords: vitiligo, psychiatric comorbidity, pediatrics, propensity matching, health disparities, dermatology, mental health, TriNetX, skin of color, autoimmune disease, electronic health records, quality of life

The study was led by PhD student Maria Östman of the University of Oslo and colleagues, who exploited one of the fastest and most complete vaccine introductions in Europe as a natural experiment. When Norway added the monovalent Rotarix vaccine to its national childhood immunisation programme in September 2014, uptake among infants reached 92.8 percent within a short period. That near-total and abrupt shift created a clean dividing line in the population: children born before the introduction had essentially no rotavirus vaccination in infancy, while those born after it were overwhelmingly vaccinated. Such a sharp exposure boundary is rare in epidemiology, and it allowed the researchers to compare diabetes incidence across birth cohorts with unusual clarity.

Rotavirus is a highly common virus transmitted by the faecal–oral route and a leading cause of severe gastroenteritis in young children, particularly those under five years of age. Immunity builds with each infection, so repeat infections tend to be milder, but first infections can be dangerous. Rotavirus vaccines, which are oral live-attenuated products made from a laboratory-weakened virus, have dramatically reduced hospitalisation and mortality from severe rotavirus disease worldwide. Because viral infections have long been suspected of influencing the risk of type 1 diabetes — an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas — researchers have debated whether rotavirus vaccination might either raise or lower diabetes risk. Previous studies in other countries have produced conflicting results, with some suggesting a protective effect and others finding no association.

To resolve the question in the Norwegian setting, the researchers followed all children born in Norway between 2007 and 2019, a total of 740,744 children, from the age of six months to five years. Crucially, they ensured that the length of follow-up was identical for children born before and after the vaccine’s introduction, eliminating a common source of bias in cohort comparisons. Data collection continued until 31 December 2024. Among the full cohort, 846 children were diagnosed with type 1 diabetes before their fifth birthday. The researchers then applied an interrupted time series analysis, a statistical technique that uses the observed pre-vaccination trend to predict what incidence would have been without the intervention, and compares that prediction with the actual observed trend afterwards.

The main analysis showed a relative increase of 11 percent in type 1 diabetes incidence among children born after the vaccine’s introduction compared with the predicted trend. In a separate adjusted analysis, the relative hazard ratio for children fully vaccinated with two doses of the monovalent vaccine, compared with unvaccinated children, was 1.17 — an apparent elevation that, however, did not reach statistical significance. The authors summarised their central finding bluntly: the study found no evidence for a reduced risk of type 1 diabetes after the introduction of rotavirus vaccination in infancy, but instead found that incidence before age five increased after vaccination was introduced. Taken at face value, that combination of results could have fuelled concerns about the vaccine’s safety.

It is here that the study’s secondary analyses become decisive. To test whether the observed increase was genuinely attributable to the rotavirus vaccine, the researchers examined what happened to diabetes incidence after other, unrelated changes to the Norwegian immunisation programme. These served as negative controls: there is no biological or epidemiological evidence that the introduction of the hepatitis B vaccine in 2016, or the switch from the 7-valent to the 13-valent pneumococcal vaccine in 2011, would affect type 1 diabetes risk. If the association seen after the rotavirus rollout reflected a true vaccine effect, similar associations should not appear around these unrelated programme changes. Yet they did. The incidence of type 1 diabetes among children born after the hepatitis B vaccine’s introduction rose by a magnitude similar to that seen after the rotavirus rollout, and the same pattern followed the pneumococcal vaccine switch.

The authors interpret this convergence as strong evidence that the initial 11 percent finding is probably not related to the rotavirus vaccine at all, but rather to other, as yet unknown changes in the environment affecting Norwegian children. Type 1 diabetes incidence has generally been increasing over recent decades, with year-to-year fluctuation, and the researchers emphasise that they do not believe any of the changes in the national vaccination programme, individually or in combination, explain the rise. As they put it, despite their best efforts to design the study to remove the influence of other unknown factors, the identical pattern appearing around every programme change — including changes hypothesised to have opposite or null effects — points to unidentified environmental factors operating across the period.

The team also systematically considered alternative explanations for the observed increase. The COVID-19 pandemic, which was followed in many countries by a temporary surge in paediatric type 1 diabetes diagnoses, was one candidate; Norway itself experienced a temporary increase in incidence in 2022 followed by a decrease. However, a recent study of Swedish and Norwegian adolescents found no increase in type 1 diabetes incidence after COVID-19 infection, weakening that hypothesis. The researchers also examined a change in Norwegian prenatal care guidelines in June 2018, which began recommending measurement of serum ferritin concentration in the first trimester of pregnancy to determine the need for iron supplementation, replacing the less sensitive measurement of haemoglobin at week 30. Because high iron levels have been suspected of association with type 1 diabetes, the change warranted scrutiny. The authors concluded it was unlikely to be relevant, noting that iron levels are usually low in pregnancy and that only children born in 2019 within the study window were affected by the new recommendations.

The authors are careful about the limits of their conclusions. They state that they do not believe rotavirus vaccination increases the risk of type 1 diabetes, but they also argue that additional studies of rotavirus vaccination and type 1 diabetes are needed in different settings and with different vaccines before any definitive conclusion is drawn. This matters because vaccine formulations differ across countries: Norway and the United Kingdom use the monovalent Rotarix vaccine alone, Germany and Italy use both Rotarix and the pentavalent RotaTeq vaccine, while Finland and Iceland implemented RotaTeq alone. Replication across these different exposure profiles would help determine whether the Norwegian findings hold elsewhere or are artefacts of local circumstances. The authors also stress the broader need for research into other environmental factors that could be associated with type 1 diabetes, given that the disease’s incidence continues to climb in many populations without a fully established cause.

For the public, the practical message is one of reassurance grounded in methodological rigour. Rotavirus vaccination has efficiently reduced hospitalisation and mortality from severe rotavirus infections in children, and the Norwegian data, once subjected to negative-control scrutiny, do not support the idea that the vaccine drives diabetes risk in early childhood. The study instead illustrates a subtle pitfall of interrupted time series designs: when a long-running upward trend in a disease coincides with a policy change, the change can appear causal even when it is not. By testing the same pattern against interventions with no plausible link to diabetes, the Oslo team showed that the 11 percent rise was more plausibly a marker of some other environmental shift affecting children born from September 2014 onward. The authors declare no conflict of interest, and their work stands as a model of how vaccine safety signals should be interrogated — thoroughly, transparently, and with controls designed to catch spurious associations before they harden into public fear.

Subject of Research: Association between rotavirus vaccination and type 1 diabetes incidence in Norwegian children

Article Title: Nationwide study in Norway shows a relative 11% increase in incidence of type 1 diabetes in children aged 0.5 to 5 years after nationwide introduction of rotavirus vaccine, but secondary analyses suggest vaccine probably not the cause

Article References: Nationwide study in Norway shows a relative 11% increase in incidence of type 1 diabetes in children aged 0.5 to 5 years after nationwide introduction of rotavirus vaccine, but secondary analyses suggest vaccine probably not the cause. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 1 diabetes, rotavirus vaccine, Rotarix, Norway, EASD, Diabetologia, interrupted time series, childhood immunisation, epidemiology, negative controls, autoimmune disease, vaccine safety

Cutaneous lupus erythematosus is the skin-limited form of a spectrum of autoimmune conditions that also includes systemic lupus erythematosus, the multi-organ disease most people associate with the word lupus. In its cutaneous forms, the immune system mounts an inflammatory attack on the skin, producing characteristic lesions that range from the well-demarcated, scarring discoid plaques to the more transient, sun-exposed rashes of subacute cutaneous lupus. Because the lesions of many patients cluster on the face, the V of the neck, the forearms, and other areas that receive the most sunlight, clinicians have long suspected that ultraviolet light is a dominant trigger. The new review, authored by Julia Ross and Aster Workineh as co-first authors, together with Rachel Breidbart, Sarika Ramachandran, Matthew D. Vesely, Jeff R. Gehlhausen, Jeffrey M. Cohen, and senior author Alicia J. Little, was designed to document the clinical profile of photosensitivity in a real-world cohort of patients seen at one academic center.

The scientific rationale for studying photosensitivity in lupus runs deep. Ultraviolet radiation, particularly in the UVB range around 290 to 320 nanometers but also in the longer UVA band, is known to injure keratinocytes, the dominant cells of the epidermis. In susceptible individuals, this injury is thought to provoke the redistribution of nuclear antigens, including components such as Ro/SSA, to the cell surface, where they become visible to the immune system. Autoantibodies that recognize these antigens can then bind the exposed targets, recruit complement, and draw inflammatory cells into the skin. The result is the characteristic photodistributed inflammation of cutaneous lupus. This mechanistic framework, developed over decades of laboratory and clinical work, explains why photosensitivity is not simply a symptom of lupus but is intertwined with its immunological engine.

Earlier epidemiological work has underscored how frequent this trigger is. A widely cited study by Foering and colleagues published in the Journal of the American Academy of Dermatology in 2012 examined the prevalence of self-reported photosensitivity in cutaneous lupus and found that a large majority of patients described their skin as abnormally reactive to sunlight. A follow-up analysis by the same group in 2013 characterized the clinical features of that photosensitivity in greater detail, distinguishing between patients who developed characteristic lupus lesions after sun exposure and those who experienced nonspecific reactions such as exaggerated sunburn. Work in the 1980s by Sutej and colleagues had already connected photosensitivity to the presence of anti-Ro antibodies in Black patients with systemic lupus, highlighting both the immunological and demographic dimensions of the phenomenon. A 2013 review by Kim and Chong in Photodermatology, Photoimmunology & Photomedicine synthesized the field’s understanding of how ultraviolet light drives cutaneous lupus and why responses vary between patients.

Against this backdrop, the Yale team’s retrospective review offers a contemporary, single-institution snapshot. Retrospective chart reviews occupy a distinctive niche in clinical research. They cannot establish causation the way a prospective trial can, but they capture the texture of real clinical practice: which patients are actually diagnosed, how their symptoms are recorded in the medical record, and how clinicians characterize the relationship between sun exposure and disease activity in routine care. In an era when much lupus research is driven by registry data and large administrative databases, a careful chart review from one academic dermatology practice provides a granular, clinically grounded counterpoint, documenting what photosensitivity actually looks like in the examination room rather than in a survey questionnaire.

The distinction between survey-based and clinically documented photosensitivity matters more than it might first appear. Self-reported photosensitivity, the measure used in many prior studies, can encompass a wide range of experiences, from a patient who develops a classic subacute lupus rash after a day at the beach to one who simply burns more easily than friends and family. Clinical photosensitivity, as recorded by a dermatologist, tends to be anchored to observable lesions in photodistributed patterns, biopsy findings, and the temporal relationship between exposure and flare. When the two measures diverge, as earlier work suggests they sometimes do, the clinical record becomes an essential arbiter. By systematically reviewing records from a single institution, the Yale investigators aimed to clarify how often photosensitivity is formally recognized among cutaneous lupus patients and how it is characterized in clinical documentation.

Why does this matter for patients? Photosensitivity is not a cosmetic nuisance. In cutaneous lupus, ultraviolet-triggered flares can produce disfiguring, scarring lesions, particularly in discoid disease, where inflammation can destroy hair follicles and leave permanent alopecia and pigmentary change. Repeated flares drive cumulative damage, and the psychological burden of visible facial lesions combined with the need to avoid sunlight, a staple of social life in many cultures, is substantial. Strict photoprotection, including broad-spectrum sunscreen, protective clothing, and behavioral modification, remains a cornerstone of management for every cutaneous lupus patient, alongside antimalarial therapy such as hydroxychloroquine and, when needed, topical or systemic immunosuppressants. Precise clinical characterization of photosensitivity helps clinicians tailor this advice and helps researchers design trials of photoprotective and immunomodulatory interventions.

The new study also speaks to a broader and increasingly urgent theme in dermatology: the interplay between autoimmune skin disease and demographics. Prior work, including the Sutej study linking photosensitivity and anti-Ro antibodies in Black patients with systemic lupus, has shown that the expression of photosensitivity can vary across populations, with implications for diagnosis and equity in care. Lupus disproportionately affects women and people of African, Hispanic, and Asian ancestry, yet the evidence base for cutaneous disease in these groups has historically been thin. Single-institution reviews, particularly at academic centers serving diverse patient populations, contribute to correcting that imbalance by documenting how the disease presents in the patients clinicians actually see. The Yale study’s funding, which included a Dermatology Foundation Diversity Research Supplement Award supporting co-first author Aster Workineh, reflects institutional recognition of that need.

Methodologically, the study was a team effort in the modern mold. Ross and Breidbart compiled the clinical data for statistical analysis, Workineh performed the statistical analysis and prepared the study’s tables, and the full author group, spanning the Department of Dermatology and the Department of Biomedical Informatics and Data Science at Yale as well as the Frank H. Netter MD School of Medicine and the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, reviewed the manuscript. The authors declared no competing interests for the study itself, although individual disclosures note consulting and investigator relationships with pharmaceutical companies unrelated to the conduct of this review. The research letter format, concise by design, signals that the findings are intended as focused clinical observations that complement, rather than replace, the larger epidemiological studies that preceded them.

What emerges from this body of work, taken together, is a picture of photosensitivity as a defining, measurable, and clinically consequential feature of cutaneous lupus erythematosus. The mechanistic story, ultraviolet-induced antigen exposure meeting a primed autoimmune response, is increasingly well understood, yet the clinical picture remains heterogeneous: patients differ in which wavelengths trigger their disease, in the type and severity of their reactions, and in how reliably those reactions are captured in the medical record. Studies like the Yale review sharpen the clinical end of that picture, grounding laboratory models in documented patient experience. For the millions of people worldwide living with lupus, the practical message is unchanged but newly reinforced: sunlight is a genuine disease trigger, meticulous photoprotection is a daily medical intervention rather than a lifestyle preference, and clinicians who ask carefully about sun-reactive skin symptoms are gathering some of the most diagnostically valuable information available. As research continues to connect the immunology of ultraviolet injury with the realities of patient care, the humble observation that sunshine makes lupus worse is proving to be one of the most scientifically productive clues in autoimmune dermatology.

Subject of Research: Photosensitivity in patients with cutaneous lupus erythematosus

Article Title: Clinical insights into photosensitivity among patients with cutaneous lupus erythematosus: a retrospective review at a single institution

Article References: Ross, J., Workineh, A., Breidbart, R., Ramachandran, S., Vesely, M. D., Gehlhausen, J. R., Cohen, J. M., & Little, A. J. (2026). Clinical insights into photosensitivity among patients with cutaneous lupus erythematosus: a retrospective review at a single institution. Archives of Dermatological Research, 318(1), Article 491. https://doi.org/10.1007/s00403-026-04987-9

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04987-9

Keywords: cutaneous lupus erythematosus, photosensitivity, ultraviolet radiation, autoimmune disease, dermatology, anti-Ro antibodies, systemic lupus erythematosus, photoprotection, retrospective review, skin lesions, Yale School of Medicine, UVB

The central challenge the researchers set out to address is a familiar one in human genetics. Most of the thousands of genetic variants identified by genome-wide association studies as risk factors for disease do not lie within protein-coding genes. Instead, they sit in regulatory regions of the genome, the stretches of DNA that control when, where, and how strongly genes are switched on. Decades of work have established this pattern, but translating a regulatory variant into a concrete molecular mechanism has remained difficult, because the field lacked an empirical framework for characterizing the downstream consequences of regulatory variation at population scale.

Single-cell molecular quantitative trait locus mapping, a technique that links genetic variants to gene regulation measured in individual cells, has emerged as a promising approach. However, previous efforts suffered from limited statistical power and, crucially, from the inability to measure chromatin state and gene expression simultaneously in the same cells. Without both layers of information, researchers could observe that a variant was associated with changes in gene expression or with changes in chromatin accessibility, but they could not reliably connect the two steps into a single causal chain running from DNA accessibility through to transcript output.

To overcome these limitations, the consortium performed paired single-nucleus RNA sequencing and single-nucleus assay for transposase-accessible chromatin sequencing on peripheral blood mononuclear cells from FinnGen donors, capturing roughly ten million nuclei. The resulting atlas identified 51,083 cis-expression quantitative trait loci affecting 20,829 genes, 338,100 cis-chromatin accessibility quantitative trait loci affecting 210,584 open chromatin peaks, 119,094 putative causal variants, and 593,765 statistical links between regulatory peaks and the genes they control. These numbers represent a resource of extraordinary depth, spanning the major classes of immune cells found in blood and providing cell-type-resolved maps of genetic regulation.

A key analytical insight came from classifying variants according to whether they completed the full regulatory cascade. Variants that altered chromatin accessibility and were also linked, through a peak-gene connection, to altered gene expression showed twice the rate of colocalization with disease associations compared with variants that affected chromatin alone. In other words, the variants most likely to be genuinely causal for disease are those whose effects can be traced through the entire chain, from open chromatin to enhancer activity to target gene expression. This finding provides a practical filter for prioritizing candidate causal variants in complex disease loci.

To validate these statistical findings experimentally, the team turned to massively parallel reporter assays, a high-throughput technique that tests the regulatory activity of thousands of DNA sequences simultaneously. The assays confirmed the regulatory effects of 10,428 fine-mapped molecular quantitative trait loci, providing direct experimental support for a substantial fraction of the atlas’s predictions and demonstrating that the computational framework captures biologically real regulatory variation rather than statistical artifacts.

Perhaps the most conceptually significant discovery concerns genes under strong evolutionary constraint, those whose sequences change rarely because mutations are harmful. Previous studies had noted a paradox: disease variants preferentially target constrained genes, yet constrained genes appear depleted of detectable expression quantitative trait loci. The new atlas resolves this contradiction by revealing a phenomenon the authors call multilayered regulatory buffering. At constrained genes, chromatin accessibility changes caused by variants occur with normal effect sizes, but their transmission to gene expression is attenuated because these genes are regulated through weaker and more numerous enhancer-gene links. The redundancy of many weak regulatory connections dampens the expression consequence of any single regulatory perturbation.

Crucially, the reporter assay experiments confirmed that this buffering operates downstream of the regulatory element itself. Constraint acts at the interface between chromatin and expression rather than on the intrinsic activity of the cis-regulatory DNA. This distinction matters because it explains why the paradox exists in the first place: standard expression quantitative trait locus studies measure only the final output, and buffering at the chromatin-to-expression step suppresses that output signal even when the underlying chromatin effects are intact. The finding reconciles apparently conflicting observations across the field and suggests that disease risk at constrained genes may accumulate through subtle, distributed effects that individual expression studies systematically miss.

The atlas also delivers concrete mechanistic hypotheses for specific diseases. At autoimmune loci, the researchers traced complete regulatory cascades at TICAM1, an adaptor protein in Toll-like receptor signaling, and RHOH, a small GTPase involved in T cell receptor signaling, both linked to autoimmune hypothyroidism. They similarly dissected Finnish-enriched variants at TNRC18 and IL21R, the latter a receptor for an interleukin with established roles in T cell biology. Beyond blood-related traits, the framework explained associations in other tissues, including loci connected to Alzheimer’s disease such as PILRB and TYROBP, genes involved in microglial signaling, illustrating that regulatory mechanisms mapped in immune cells can illuminate neurological and other complex diseases.

The resource is being made broadly available to the research community. Summary statistics for chromatin accessibility quantitative trait loci, expression quantitative trait loci, and peak-gene links are publicly accessible and browsable through an interactive web interface, and the analysis pipelines, including the CASCADE classification framework and supporting software packages, have been released on GitHub. Individual-level data remain protected under Finnish and European data regulations but can be accessed by approved researchers through established application channels. As the field moves toward functional interpretation of the ever-growing catalog of disease-associated variants, atlases of this kind, which connect genetic variation to regulatory architecture across millions of cells and hundreds of donors, are likely to become foundational references for drug target discovery and precision medicine in immunology and beyond.

Subject of Research: Population-scale single-cell multiomic mapping of regulatory genetic variation in human immune cells

Article Title: Population-scale immune multiome atlas reveals regulatory disease mechanisms

Article References: Kanai, M., Delorey, T. M., Honkanen, J., Rodosthenous, R. S., Juvila, J., Murphy, S., Teixeira-Soldano, I., Hwang, H. S., Karjalainen, J., Halonen, J., Panagiotaropoulou, G., Zhang, Y., McCabe, C., Chen, E., Nanki, K., Yoshida, T., Liu, K., Glean, M., Mehrotra, N., … Xavier, R. J. (2026). Population-scale immune multiome atlas reveals regulatory disease mechanisms. Nature. https://doi.org/10.1038/s41586-026-11078-2

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11078-2

Keywords: single-cell multiomics, chromatin accessibility, gene expression, quantitative trait loci, FinnGen, immune cells, regulatory variants, enhancer-gene links, autoimmune disease, genetic fine-mapping, reporter assays, evolutionary constraint

Sjögren’s disease is best known as a chronic autoimmune disorder that dries out the mouth and eyes by destroying exocrine glands, but in a substantial minority of patients it turns its inflammatory sights on the nerves themselves. Neurological involvement is reported in roughly 8 to 49 percent of cases, averaging around 20 percent, and it can strike both the peripheral nervous system, causing neuropathies, and the central nervous system, producing encephalitis, myelitis, or vasculitis. When it does, the consequences can be severe: disability, poor prognosis, and markedly reduced quality of life. Neurologists and rheumatologists call this presentation Neuro-Sjögren, and it is notoriously hard to pin down.

The difficulty lies in the disease’s habit of hiding. Some patients arrive with neurological symptoms as their first and only complaint, lacking the characteristic sicca symptoms of dryness and testing negative for anti-SSA, the antibody that anchors most Sjögren’s diagnoses. Studies cited by the authors indicate that the average diagnostic delay for Neuro-Sjögren stretches from three to six years, and that the wait is even longer in patients who are anti-SSA positive or who first present with neurological symptoms. Every year of delay is a year in which an autoimmune process may be quietly damaging nerves that cannot easily repair themselves.

Enter the labial gland biopsy. The procedure involves removing a small cluster of minor salivary glands from the inner lip and having a pathologist count lymphocytic foci, dense aggregates of at least 50 mononuclear immune cells, per 4 square millimeters of tissue. A focus score of 1 or higher is not diagnostic on its own, but it is a key component of the 2016 ACR/EULAR classification criteria for Sjögren’s disease and can support a clinical diagnosis when combined with other findings. The test is not trivial: it carries risks of local scarring, infection, and permanent numbness, and it demands both an experienced clinician and expert pathological interpretation. That is precisely why knowing who truly benefits from it matters.

The Beijing team, led by Zhen Tian and colleagues, enrolled 456 hospitalized patients with suspected Sjögren’s disease, of whom 412 met the inclusion criteria. Within this cohort, 135 patients had suspected Neuro-Sjögren, meaning their neurological symptoms had been confirmed by a neurologist and, wherever possible, corroborated by objective evidence such as MRI, PET, nerve conduction studies, electromyography, or cerebrospinal fluid analysis. The remaining 277 patients, suspected of Sjögren’s without neurological involvement, served as a comparison group. The researchers deliberately excluded patients whose neurological complaints could be explained by alternative diagnoses, and they excluded anyone with other connective tissue diseases, recent malignancy, active infection, or conditions making biopsy unsafe.

The diagnostic pathway followed real-world practice. Patients who were anti-SSA positive and had objective evidence of glandular impairment could be classified under the 2016 ACR/EULAR criteria without a biopsy. Everyone else, whose serological and glandular findings were insufficient, underwent labial gland biopsy as part of the work-up. Among the 135 suspected Neuro-Sjögren patients, 91 fell into this biopsy-required category, compared with 44 who could be classified without histology. The numbers tell a striking story: biopsy was required in 67.4 percent of suspected Neuro-Sjögren patients versus 56.3 percent of the non-neurological group, a statistically significant difference. Even more compelling, when a biopsy was performed, it came back positive, with a focus score of at least 1, in 81.3 percent of the Neuro-Sjögren group versus just 51.3 percent of the others.

The most eye-catching figure concerns the patients clinicians worry about most. Among anti-SSA-negative patients with suspected Neuro-Sjögren, the biopsy positivity rate reached 77.3 percent. In other words, for roughly three out of four patients who lacked the classic antibody and whose glandular tests were uninformative, the lip biopsy still revealed the focal lymphocytic inflammation that defines Sjögren’s disease. Only 12 patients in the cohort were both anti-SSA negative and biopsy negative, and these individuals could not be classified as having Sjögren’s disease under the 2016 criteria. For a population where diagnosis often stalls for years, that is a meaningful yield from a procedure taking minutes.

Who, then, ends up needing the biopsy? Multivariable logistic regression identified two independent predictors of biopsy requirement: younger age at onset, with an odds ratio of 0.960 per year of age, and early-onset neurological symptoms, meaning neurological manifestations that appeared before the typical sicca symptoms, which more than tripled the odds at an odds ratio of 3.634. In the biopsy-required group, 65.9 percent of patients had presented with neurological symptoms first, compared with 36.4 percent of those classified without biopsy. Conversely, anti-SSB positivity and antinuclear antibody titers of 1:320 or higher were independently associated with a lower likelihood of needing a biopsy, presumably because such patients already carried stronger serological evidence. Elevated IgG showed only a borderline association. The authors are careful to note that these factors reflect their center’s diagnostic pathway, not intrinsic properties of the disease, and should not be read as universal indications for or against biopsy.

Among the patients who actually underwent biopsy, a second pattern emerged. Those with positive results more frequently showed higher erythrocyte sedimentation rates, elevated IgG, and ANA titers of at least 1:320 than biopsy-negative patients. The researchers interpret these as non-specific markers of broader immune activation rather than disease-specific signatures, cautioning that they should never be used in isolation to justify the procedure. Interestingly, while the difference was not statistically significant, biopsy positivity was numerically higher in patients with peripheral nervous system involvement, 87.2 percent, than in those with central nervous system involvement, 77.1 percent, hinting that peripheral phenotypes may be more tightly linked to histopathological glandular inflammation. The study also noted, contrary to much prior literature, a slightly higher proportion of central than peripheral involvement in their cohort, which the authors attribute to center-specific referral patterns and neurological expertise.

The findings align with a growing body of work. Previous studies have shown that positive labial gland biopsies associate with autonomic dysfunction, that more than 90 percent of patients with sensory ganglionopathy test positive on both Schirmer’s test and biopsy despite few sicca symptoms, and that among patients with small fiber neuropathy, up to 30 percent are ultimately diagnosed with Sjögren’s disease. The Beijing study adds a quantitative framework: in serologically ambiguous patients with neurological presentations, the biopsy is not a last resort but frequently the decisive test. The authors acknowledge the limitations of their retrospective, single-center design, including possible selection bias toward more complex inpatient cases and the modest number of outcome events in their regression model. They call for prospective, multicenter studies with richer histological profiling. Still, the practical message for clinicians is clear: when a patient, especially a younger one, presents with neurological symptoms that precede any dryness, and the antibody panel comes back empty, the small glands of the lower lip may hold the answer that blood tests cannot.

Subject of Research: Clinical utility of labial gland biopsy in diagnosing suspected Neuro-Sjögren

Article Title: The Clinical Utility of Labial Gland Biopsy in Patients With Suspected Neuro‐Sjögren

Article References: Tian, Z., Li, X., Li, X., Wang, Y., Wang, C., & Zhao, Y. (2026). The Clinical Utility of Labial Gland Biopsy in Patients With Suspected Neuro‐Sjögren. Immunity, Inflammation and Disease, 14(9), Article e70507. https://doi.org/10.1002/iid3.70507

Image Credits: AI Generated

DOI: 10.1002/iid3.70507

Keywords: Neuro-Sjögren, Sjögren's disease, labial gland biopsy, focus score, anti-SSA, autoimmune disease, peripheral neuropathy, central nervous system, ACR/EULAR criteria, diagnostic delay, small fiber neuropathy, rheumatology

The genetic roots of FSHD lie in a region of chromosome 4 called D4Z4, a stretch of repeated DNA sequences that normally keeps a gene called DUX4 silenced. In FSHD1, which accounts for about 95 percent of cases, these repeats contract to between one and ten units instead of the usual eleven or more, allowing DUX4 to be aberrantly expressed in muscle tissue. DUX4 is a transcription factor that wreaks havoc once activated, driving oxidative stress, impaired muscle regeneration, and the activation of innate immune and antiviral pathways. The shorter the residual repeat array, the more DUX4 is released and, generally, the earlier and more severe the disease. But this relationship is far from complete. Even relatives carrying identical D4Z4 contractions can differ dramatically in severity, a gap that has long suggested the involvement of additional modifiers, whether genetic, epigenetic, environmental, or immunological.

That immunology might matter in FSHD is not an entirely new idea. Muscle biopsies from patients frequently show inflammatory infiltrates dominated by CD8-positive T lymphocytes and macrophages, and magnetic resonance imaging reveals muscle edema during active phases of the disease. Transcriptomic studies have documented upregulation of interferon signaling and cytokine-related genes in FSHD tissues, and DUX4 itself can induce the expression of inflammatory mediators. Isolated case reports have also described patients with both FSHD and autoimmune conditions such as myasthenia gravis or inflammatory myopathies. What remained unknown was whether these co-occurrences were coincidental or whether autoimmune disease systematically shapes the course of the muscular dystrophy.

To answer that question, the Nice team analyzed 299 adults with genetically confirmed FSHD1, all evaluated between 2017 and 2025, for whom complete demographic, clinical, and genetic data were available. Each patient was classified using the Comprehensive Clinical Evaluation Form, a standardized tool that sorts patients into four categories: category A for the typical facial and scapular phenotype, category B for incomplete weakness limited to the scapular or facial muscles, category C for pauci-symptomatic or asymptomatic carriers, and category D for atypical presentations. Autoimmune diagnoses were only accepted when confirmed by the relevant specialist, with strict criteria applied for conditions such as Sjögren’s syndrome, which required fulfillment of the 2016 ACR/EULAR classification criteria with positive anti-SSA or anti-SSB antibodies.

The results were striking. Eighty-two patients, or 27.4 percent of the cohort, had at least one autoimmune disease, and fourteen of them carried two. In total, 96 autoimmune conditions spanning fourteen distinct diagnoses were recorded. Hashimoto’s thyroiditis was the most common, affecting 32 patients, followed by autoimmune diabetes in 16, atopic dermatitis in 12, myasthenia gravis in 10, and primary biliary cholangitis and psoriasis in 7 each. When the researchers compared these counts with published prevalence estimates from the general population, several conditions stood out as dramatically overrepresented. Myasthenia gravis appeared roughly 167 times more often than expected, primary biliary cholangitis about 106 times, autoimmune diabetes nearly 43 times, idiopathic inflammatory myositis about 72 times, and Sjögren’s syndrome more than 16 times. By contrast, common inflammatory skin disorders such as atopic dermatitis and psoriasis were not enriched, suggesting that the association involves specific autoimmune mechanisms rather than a generalized tendency toward inflammation.

The clinical implications were equally compelling. Patients with autoimmune comorbidities were older at examination, with a mean age of 56.3 years compared with 51.2 years, and had a later disease onset, at 38.4 years versus 33.7 years. More intriguingly, despite carrying significantly larger D4Z4 repeat arrays, 7.18 repeat units on average versus 6.53, which should ordinarily predict a milder disease, these patients scored significantly worse on the FSHD severity scale, 7.98 versus 6.56. The distribution of phenotypes also shifted: autoimmune patients were far more likely to fall into category D, the atypical group, at 30.5 percent versus 8.3 percent of non-autoimmune patients, and less likely to show the classical category A presentation. Within categories A and B, autoimmune patients again had significantly higher severity scores.

To test whether autoimmunity was an independent driver of severity rather than a byproduct of age or genetic background, the researchers built a multivariable linear regression model incorporating age, sex, disease duration, D4Z4 repeat number, and autoimmune status. The genetic effect held firm: each additional repeat unit was associated with a decrease in severity score of nearly one point, with a beta coefficient of minus 0.96, while each additional year of disease duration added 0.11 points. But the autoimmune signal was even more pronounced. After adjusting for every other variable, the presence of an autoimmune disease added an average of 2.12 points to the severity score, an effect that was highly statistically significant. Notably, there was no interaction between autoimmune status and repeat number, meaning the autoimmune penalty appeared to operate in parallel with, rather than through, the primary genetic defect.

Perhaps the most provocative finding concerns the subgroup of patients carrying seven to ten D4Z4 repeat units, the larger residual arrays conventionally associated with milder disease. Autoimmune disease was substantially more frequent in this group, affecting 36.1 percent of patients with seven to ten repeats compared with just 16.2 percent of those with shorter alleles, and 73 of the 96 recorded autoimmune conditions occurred in the larger-repeat subgroup. The authors propose a conceptual model in which the relative contribution of disease modifiers depends on repeat size. In patients with short alleles, below seven repeats, the primary genetic contraction dominates the clinical picture. In those with larger alleles, however, secondary factors, including autoimmune disease, unrelated genetic disorders, hormones, telomere shortening, aging, and immunosenescence, may play a proportionally greater role in shaping phenotype and severity. This could explain why patients with seemingly mild genetics sometimes develop serious disease, and why the seven-to-ten repeat range appears repeatedly as a hotspot for modifier effects in this and previous studies from the same group.

The biological mechanisms linking autoimmunity and FSHD severity remain speculative but plausible. Chronic muscle injury in FSHD may release intracellular antigens and pro-inflammatory mediators that fuel immune activation, while systemic autoimmune inflammation could in turn exacerbate muscle dysfunction, impair regeneration, or interact with the epigenetic regulation of the D4Z4 locus itself. The later disease onset observed in autoimmune patients hints that an age-related pro-inflammatory state, compounded by immunosenescence, may gradually tip the balance in genetically susceptible individuals. The authors are careful to note that their study is retrospective and single-center, that referral bias may have inflated the detection of autoimmune comorbidities in a national neuromuscular center, and that several rare conditions were represented by too few cases for firm conclusions. Still, the message for clinical practice is clear: systematically screening FSHD patients for autoimmune disease could refine prognosis and, if future longitudinal studies confirm causality, open the door to immune-targeted therapies for a subgroup of patients whose disease severity is being quietly amplified by their own immune systems.

Subject of Research: The association between autoimmune comorbidities and clinical severity in facioscapulohumeral muscular dystrophy type 1

Article Title: Autoimmune Comorbidities as Modifiers of Phenotypic Heterogeneity in Facioscapulohumeral Dystrophy

Article References: Pini, J., Tammam, G., Ezaru, A., Gambella, M., Sanson, B., Villa, L., Cavalli, M., Ioncea, M.-B., Puma, A., & Sacconi, S. (2026). Autoimmune Comorbidities as Modifiers of Phenotypic Heterogeneity in Facioscapulohumeral Dystrophy. Annals of Clinical and Translational Neurology, Article acn3.70529. https://doi.org/10.1002/acn3.70529

Image Credits: AI Generated

DOI: 10.1002/acn3.70529

Keywords: FSHD, muscular dystrophy, autoimmune disease, DUX4, D4Z4, myasthenia gravis, Hashimoto's thyroiditis, disease modifiers, genetics, inflammation, clinical severity, neuromuscular disorders

The stakes of this distinction are considerable. IgG4-related disease generally responds to glucocorticoids and other immunomodulatory therapies, whereas diffuse large B-cell lymphoma, often abbreviated DLBCL, requires chemotherapy, radiotherapy, or other oncological interventions. If the autoimmune condition is mistaken for cancer, patients may undergo unnecessary and potentially harmful treatment, including organ resection, which has been reported in this setting. If the lymphoma is missed, effective therapy is delayed, and DLBCL’s aggressive biology leaves little room for hesitation. Around 40 percent of DLBCL patients present with disease outside the lymph nodes, and population data from China reported an overall five-year survival of roughly 38.3 percent for lymphoma in 2018, underscoring how much depends on early recognition.

The research team, led by Yongkang Chen, Weimiao Li, and colleagues, assembled a cohort of 56 newly diagnosed patients treated between January 2012 and October 2025: 19 with IgG4-related disease and 37 with DLBCL, all of whom presented with lymphadenopathy. IgG4-related disease cases were classified using the 2019 American College of Rheumatology and European League Against Rheumatism criteria or the 2011 Japanese comprehensive diagnostic criteria, while every DLBCL diagnosis was confirmed by experienced hematopathologists according to the World Health Organization classification. Within the first 24 hours of admission, the researchers extracted 62 variables from each patient, spanning demographics, complete blood counts, biochemistry, coagulation panels, and selected immunological tests.

The initial comparison revealed 20 variables that differed significantly between the two groups, including disease duration, white blood cell count, eosinophil percentages, red cell indices, prothrombin time, serum total protein, globulin, the albumin-to-globulin ratio, creatinine, sodium, bicarbonate, lactate dehydrogenase, and both complement C3 and C4. Many of these differences fit the underlying biology. IgG4-related disease is characterized by chronic immune activation, expansion of circulating plasmablasts, and hypergammaglobulinemia, which explains the markedly higher serum globulin and total protein concentrations in that group. Complement levels, too, were substantially lower in the IgG4-related disease patients, a finding consistent with the complement consumption that has been described in this disorder.

To distill these signals into something clinically usable, the team ran the five most promising candidates through univariate and then multivariable logistic regression. Three variables survived simultaneous adjustment for the others: lymphocyte count, serum total protein, and prothrombin time, or PT. Lymphocyte counts were higher in IgG4-related disease than in DLBCL, averaging 1.80 versus 1.17 billion cells per liter, a pattern the authors interpret as reflecting the contrasting systemic immune states of the two illnesses. DLBCL is associated with a peripheral immunosuppressive profile, even though higher infiltration of T cells and non-malignant B cells within lymphoma tissue is linked to better survival. IgG4-related disease, by contrast, features expansion of CD4-positive T helper 2 and follicular helper T cell subsets, in keeping with the dense lymphoplasmacytic infiltrates seen in affected tissues.

Serum total protein tells a complementary story. In IgG4-related disease, sustained polyclonal B-cell activation drives the production of immunoglobulins across multiple subclasses, not just IgG4, and proteomic studies have documented elevations of IgG1, IgG2, and acute-phase proteins such as alpha-1-antitrypsin. This flood of circulating antibodies raises the measured total protein concentration. DLBCL, on the other hand, is associated with tumor-related alterations of the serum proteome, and increased catabolism or impaired nutritional status can push total protein toward normal or reduced values. The authors are careful to note that total protein is an integrated signal rather than a disease-specific marker, capturing inflammation, nutrition, and tumor metabolism all at once.

The third predictor, prothrombin time, is the most unexpected. PT assesses the extrinsic coagulation pathway and is ordinarily used to monitor anticoagulation or liver function, yet it was longer in IgG4-related disease patients than in those with DLBCL, 11.61 versus 10.91 seconds. The authors offer several speculative explanations: tumor-associated tissue factor and inflammatory signaling may promote coagulation activation in lymphoma, shortening PT, while hepatobiliary involvement or IgG4 autoantibodies against complement factor H, described in a case of complement-mediated thrombotic microangiopathy, might influence coagulation in the autoimmune condition. Because many variables were screened without formal correction for multiple testing, a chance association cannot be excluded, and the absolute difference was modest. Still, PT remained significant both in the multivariable model and in a matched sensitivity analysis restricted to biopsy-proven cases, marking it as a reproducible signal that warrants independent investigation.

Combining the three predictors, the researchers constructed a nomogram, a graphical scoring tool that converts a patient’s laboratory values into a probability of having one disease versus the other. Within the development cohort, the model achieved an area under the receiver operating characteristic curve of 0.91, with a confidence interval of 0.82 to 0.99, along with 88 percent accuracy, 84 percent sensitivity, and 89 percent specificity at the chosen cutoff. Calibration analysis produced a mean absolute error of just 0.032, indicating close agreement between predicted and observed probabilities, and decision curve analysis suggested a potential net benefit over both treat-all and treat-none strategies across a wide range of threshold probabilities.

The authors are admirably candid about the limits of these numbers. The sensitivity analysis, which matched 12 biopsy-confirmed IgG4-related disease patients to 12 age- and sex-matched DLBCL patients, reproduced the PT difference and showed similar directional trends for the other predictors, but the reduced sample size meant several variables lost statistical significance. A post-hoc power calculation based on PT estimated statistical power at only 53.8 percent, a sobering reminder of the constraints imposed by a cohort of 56 patients. The retrospective, single-center design, the absence of external validation, and the omission of disease-specific markers such as serum IgG4 and the IgG4-to-IgG ratio all temper the conclusions. The favorable AUC obtained in a small development cohort may well overstate the performance that would be observed in new patients.

Even with those caveats, the study addresses a genuine and underexplored clinical gap. Previous publications involving both diseases have mainly described their coexistence or sequential development in individual patients, and lymphoma has been reported as the most frequent malignancy occurring in association with IgG4-related disease, making the differential diagnosis a recurring practical problem. The nomogram is explicitly positioned as a supplement to, not a substitute for, pathological biopsy, which remains the diagnostic gold standard. Its most plausible role is at the initial assessment, when lymphadenopathy has overlapping features in both conditions and tissue confirmation is not yet available, giving clinicians an early, non-invasive data point to guide the urgency and direction of further work-up. Larger, independent, multicenter cohorts will be needed before the model can be considered for routine use, but the underlying message is an appealing one: sometimes the blood draw that is already being done may hold the first clue to which of two very different diseases is hiding behind an enlarged lymph node.

Subject of Research: Differentiating IgG4-related disease from diffuse large B-cell lymphoma using routine laboratory biomarkers and a predictive nomogram

Article Title: Identification of Discriminatory Factors and Construction of a Nomogram for Differentiating IgG4‐RD and DLBCL

Article References: Identification of Discriminatory Factors and Construction of a Nomogram for Differentiating IgG4‐RD and DLBCL. (n.d.). https://doi.org/10.1002/iid3.70529

Image Credits: AI Generated

DOI: 10.1002/iid3.70529

Keywords: IgG4-related disease, diffuse large B-cell lymphoma, nomogram, lymphocyte count, serum total protein, prothrombin time, lymphadenopathy, biomarkers, logistic regression, diagnostic model, autoimmune disease, hematology